SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMSHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMSGlobeNewswireJanuary 3, 2020ReblogShareTweetShareNEW YORK, Jan. 03, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ:  ADMS)  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.The investigation concerns whether Adamas and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On March 4, 2019, during a conference call with investors, Adamas walked back its previous prescription growth estimates for its primary product, Gocovri, warned of a continued slow-down in Gocovri prescriptions, and refused to make further predictions about Gocovri’s ability to achieve a sizeable market share. On this news, Adamas’s stock price fell $3.99 per share, or 32.4%, to close at $8.16 per share on March 5, 2019. Then, on September 30, 2019, a Bank of America/Merrill Lynch analyst lowered its rating for Adamas stock to “Underperform,” noting “existing overhangs for ADMS: (1) Gocovri coverage: a number of national formularies exclude Gocovri.  We expect reimbursement hurdles in [multiple sclerosis walking impairment] space especially with generic Ampyra launch.” On this news, Adamas’s stock price fell $1.55 per share, or 23.26%, to close at $5.12 per share on September 30, 2019.The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.comCONTACT:Robert S. WilloughbyPomerantz LLPrswilloughby@pomlaw.comReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoMost face masks won’t protect you from the coronavirusYahoo FinanceStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceSomething 'dangerous' is happening beneath the surface of the market selloffYahoo FinanceMarket Recap: Friday, Dec. 13Yahoo Finance VideoBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo FinanceWhat to watch in the markets: Friday, February 28Yahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo Finance